Research ExplorerPublicationsSerum carbonic anhydrase IX during first-line therapy of ova...

Serum carbonic anhydrase IX during first-line therapy of ovarian cancer.

Standard

Serum carbonic anhydrase IX during first-line therapy of ovarian cancer. / Wölber, Linn; Müller, Volkmar; Zu Eulenburg, Christine Gräfin; Schwarz, Jörg; Carney, Walter; Jänicke, Fritz; Milde-Langosch, Karin; Mahner, Sven.

In: GYNECOL ONCOL, Vol. 117, No. 2, 2, 2010, p. 183-188.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Wölber, L, Müller, V, Zu Eulenburg, CG, Schwarz, J, Carney, W, Jänicke, F, Milde-Langosch, K & Mahner, S 2010, 'Serum carbonic anhydrase IX during first-line therapy of ovarian cancer.', GYNECOL ONCOL, vol. 117, no. 2, 2, pp. 183-188. <http://www.ncbi.nlm.nih.gov/pubmed/20051287?dopt=Citation>

APA

Wölber, L., Müller, V., Zu Eulenburg, C. G., Schwarz, J., Carney, W., Jänicke, F., Milde-Langosch, K., & Mahner, S. (2010). Serum carbonic anhydrase IX during first-line therapy of ovarian cancer. GYNECOL ONCOL, 117(2), 183-188. [2]. http://www.ncbi.nlm.nih.gov/pubmed/20051287?dopt=Citation

Vancouver

Wölber L, Müller V, Zu Eulenburg CG, Schwarz J, Carney W, Jänicke F et al. Serum carbonic anhydrase IX during first-line therapy of ovarian cancer. GYNECOL ONCOL. 2010;117(2):183-188. 2.

Bibtex

@article{4e6bf7f92f274c04b3b50bd6f5ec9ba7,
title = "Serum carbonic anhydrase IX during first-line therapy of ovarian cancer.",
abstract = "OBJECTIVE: Carbonic anhydrase IX (CAIX) is primarily involved in maintaining the extracellular pH. It is overexpressed in a variety of tumors including ovarian cancer. To evaluate the potential prognostic and predictive role of serum CAIX for therapy response in ovarian cancer, we analyzed longitudinal serum samples. METHODS: One hundred forty-eight serum samples from 37 patients with primary epithelial ovarian cancer were analyzed. Samples were prospectively collected at 4 time points: (1) before radical surgery, (2) after surgery and before platinum/taxane chemotherapy, (3) during chemotherapy, and (4) after chemotherapy. Serum CAIX was quantified by ELISA and expression in tumor tissue was verified by immunohistochemistry. Correlation with response and clinical outcome as well as the tumor marker CA-125 was analyzed. RESULTS: Serum concentration of CAIX ranged between 30 and 1687 pg/mL and showed no significant changes during first-line therapy (median level before and after surgery 204 and 198 pg/mL, during and after chemotherapy 175 and 181 pg/mL). There was no association between serum CAIX and progression-free or overall survival. CA-125 decreased significantly after surgery (median serum level before and after surgery 413 and 84 kU/L, p",
author = "Linn W{\"o}lber and Volkmar M{\"u}ller and {Zu Eulenburg}, {Christine Gr{\"a}fin} and J{\"o}rg Schwarz and Walter Carney and Fritz J{\"a}nicke and Karin Milde-Langosch and Sven Mahner",
year = "2010",
language = "Deutsch",
volume = "117",
pages = "183--188",
journal = "GYNECOL ONCOL",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - Serum carbonic anhydrase IX during first-line therapy of ovarian cancer.

AU - Wölber, Linn

AU - Müller, Volkmar

AU - Zu Eulenburg, Christine Gräfin

AU - Schwarz, Jörg

AU - Carney, Walter

AU - Jänicke, Fritz

AU - Milde-Langosch, Karin

AU - Mahner, Sven

PY - 2010

Y1 - 2010

N2 - OBJECTIVE: Carbonic anhydrase IX (CAIX) is primarily involved in maintaining the extracellular pH. It is overexpressed in a variety of tumors including ovarian cancer. To evaluate the potential prognostic and predictive role of serum CAIX for therapy response in ovarian cancer, we analyzed longitudinal serum samples. METHODS: One hundred forty-eight serum samples from 37 patients with primary epithelial ovarian cancer were analyzed. Samples were prospectively collected at 4 time points: (1) before radical surgery, (2) after surgery and before platinum/taxane chemotherapy, (3) during chemotherapy, and (4) after chemotherapy. Serum CAIX was quantified by ELISA and expression in tumor tissue was verified by immunohistochemistry. Correlation with response and clinical outcome as well as the tumor marker CA-125 was analyzed. RESULTS: Serum concentration of CAIX ranged between 30 and 1687 pg/mL and showed no significant changes during first-line therapy (median level before and after surgery 204 and 198 pg/mL, during and after chemotherapy 175 and 181 pg/mL). There was no association between serum CAIX and progression-free or overall survival. CA-125 decreased significantly after surgery (median serum level before and after surgery 413 and 84 kU/L, p

AB - OBJECTIVE: Carbonic anhydrase IX (CAIX) is primarily involved in maintaining the extracellular pH. It is overexpressed in a variety of tumors including ovarian cancer. To evaluate the potential prognostic and predictive role of serum CAIX for therapy response in ovarian cancer, we analyzed longitudinal serum samples. METHODS: One hundred forty-eight serum samples from 37 patients with primary epithelial ovarian cancer were analyzed. Samples were prospectively collected at 4 time points: (1) before radical surgery, (2) after surgery and before platinum/taxane chemotherapy, (3) during chemotherapy, and (4) after chemotherapy. Serum CAIX was quantified by ELISA and expression in tumor tissue was verified by immunohistochemistry. Correlation with response and clinical outcome as well as the tumor marker CA-125 was analyzed. RESULTS: Serum concentration of CAIX ranged between 30 and 1687 pg/mL and showed no significant changes during first-line therapy (median level before and after surgery 204 and 198 pg/mL, during and after chemotherapy 175 and 181 pg/mL). There was no association between serum CAIX and progression-free or overall survival. CA-125 decreased significantly after surgery (median serum level before and after surgery 413 and 84 kU/L, p

M3 - SCORING: Zeitschriftenaufsatz

VL - 117

SP - 183

EP - 188

JO - GYNECOL ONCOL

JF - GYNECOL ONCOL

SN - 0090-8258

IS - 2

M1 - 2

ER -